Abstract |
Although it has been shown that muscle magnetic resonance imaging (MRI) improves the phenotypic characterization of patients with neuromuscular disorders and allows accurate quantification of muscle and adipose tissue distribution, to date quantitative MRI has not been used to assess the therapeutic response in clinical trials of neuromuscular diseases. We discuss quantitative MRI findings after a 6-month course of enzyme replacement therapy administered to nine patients with adult-onset glycogenosis II.
|
Authors | A Pichiecchio, G U Poloni, S Ravaglia, M Ponzio, G Germani, D Maranzana, A Costa, A Repetto, E Tavazzi, C Danesino, A Moglia, S Bastianello |
Journal | Muscle & nerve
(Muscle Nerve)
Vol. 40
Issue 1
Pg. 122-5
(Jul 2009)
ISSN: 0148-639X [Print] United States |
PMID | 19533640
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Recombinant Proteins
- alpha-Glucosidases
|
Topics |
- Age of Onset
- Aged
- Female
- Glycogen Storage Disease Type II
(drug therapy, pathology)
- Humans
- Magnetic Resonance Imaging
(methods)
- Male
- Middle Aged
- Muscle, Skeletal
(pathology)
- Recombinant Proteins
(therapeutic use)
- alpha-Glucosidases
(therapeutic use)
|